VRTX icon

Vertex Pharmaceuticals
VRTX

Overview Fund Activity
387.11 USD
-0.04
0.01%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
387.11
0.00
0%
1 day
-0.01%
5 days
-1.92%
1 month
-0.71%
3 months
-13.67%
6 months
-24.43%
Year to date
-4.6%
1 year
-18.36%
5 years
45.86%
10 years
211.78%
 

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Healthcare Biotechnology
0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 15 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

68% more call options, than puts

Call options by funds: $930M | Put options by funds: $554M

1.58% more ownership

Funds ownership: 92.08% [Q1] → 93.67% (+1.58%) [Q2]

0% less repeat investments, than reductions

Existing positions increased: 605 | Existing positions reduced: 606

4% less funds holding

Funds holding: 1,595 [Q1] → 1,536 (-59) [Q2]

7% less capital invested

Capital invested by funds: $115B [Q1] → $107B (-$7.58B) [Q2]

19% less first-time investments, than exits

New positions opened: 117 | Existing positions closed: 145

38% less funds holding in top 10

Funds holding in top 10: 26 [Q1] → 16 (-10) [Q2]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$405
5% upside
Avg. target
$482
25% upside
High target
$553
43% upside

15 analyst ratings

10  positive
67%
5  neutral
33%
0  negative
0%
Evercore ISI Group
Liisa Bayko
$475
Outperform
Maintained
11 Sep 2025
Canaccord Genuity
Whitney Ijem
$411
Hold
Maintained
6 Aug 2025
Guggenheim
Debjit Chattopadhyay
$546
Buy
Maintained
6 Aug 2025
Wells Fargo
Mohit Bansal
$460
Overweight
Upgraded
6 Aug 2025
Truist Securities
Joon Lee
$490
Buy
Maintained
5 Aug 2025
See Analyst Rankings

Financial journalist opinion

Based on 24 articles about VRTX published over the past 30 days

Neutral
Business Wire
8 hours ago
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
Neutral
Zacks Investment Research
22 hours ago
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Neutral
Zacks Investment Research
yesterday
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Positive
The Motley Fool
yesterday
2 Growth Stocks to Buy and Hold Forever
Investors who bought shares of Intuitive Surgical (ISRG -0.10%) or Vertex Pharmaceuticals (VRTX 0.68%) 20 years ago and held onto them are likely pleased with their decisions. Both companies have produced market-beating returns over the past two decades.
2 Growth Stocks to Buy and Hold Forever
Positive
The Motley Fool
yesterday
Why This Biotech Company Could Be a Growth Stock Powerhouse
When you think of adding growth to your portfolio, you may immediately envision technology stocks. After all, names like Nvidia and Meta Platforms have driven stock market gains over the past couple of years.
Why This Biotech Company Could Be a Growth Stock Powerhouse
Positive
The Motley Fool
3 days ago
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Shares of Vertex Pharmaceuticals (VRTX -0.63%) have risen more than 2,000% over the past 20 years. Despite a terrific run-up, it's hard to find an investment bank analyst on Wall Street who expects the stock to fall in the year ahead.
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Positive
Seeking Alpha
5 days ago
Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality
Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal diabetic neuropathy (DNP) data, with CF providing a solid profit floor. Pipeline diversification faces tough competition and margin pressure, so sustained outperformance depends on JOURNAVX's broader pain market success.
Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality
Positive
Zacks Investment Research
6 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Positive
The Motley Fool
6 days ago
3 Absurdly Cheap Stocks to Buy for the Long Haul
Are you looking for some quality stocks to buy at decent prices? If you're looking to buy and hold for the long term, now can be an optimal time to invest in stocks that may not be doing all that well, but that still possess some great potential in the long run.
3 Absurdly Cheap Stocks to Buy for the Long Haul
Neutral
Business Wire
7 days ago
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (.
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
See News Rankings
Charts implemented using Lightweight Charts™